The update is based on data from the FLEX study in patients with HR-positive, HER2-negative early-stage breast cancer.
CAR031's global reach," including in China, as a potential treatment for liver and other solid tumors, AbelZeta CEO Tony Liu said.
The firm filed data from the Phase III VIKTORIA-1 trial, which evaluated gedatolisib with fulvestrant with or without a CDK4/6 inhibitor.
The companies struck the deal as Atsena prepares to initiate enrollment of a pivotal cohort of its lead program in XLRS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback